Bevacizumab for glioblastoma-a promising drug or not?

ABSTRACT: Two double blind, placebo-controlled, and randomized phase III studies were conducted, and the results including OS's were reported at the ASCO Meeting in June 2013, which was the beginning of confusion surrounding this topic. This is a review article not only summarizing the previous evidence, but also looking beyond.

SUBMITTER: Nagane M 

PROVIDER: S-EPMC3875948 | biostudies-literature | 2013 Nov

REPOSITORIES: biostudies-literature